Chemoradiotherapy plays an important role in the treatment of hypopharyngeal cancer. At Kyushu University, patients with hypopharyngeal cancer are initially treated with 30-40 Gy of irradiation with chemotherapy. The patients who demonstrate a good response continue to receive further radiotherapy. The other patients with poor response to radiotherapy receive surgery. In 44 patients with stage I-II hypopharyngeal cancer, 32 patients received chemoradiotherapy and 11 patients received surgery. There were no significant differences in 5-year disease-specific survival rates between the two groups (88.4% vs 90.9%). Local control with laryngeal voice preservation was achieved in 8 (88.9%) of 9 patients with stage I disease, and in 23 (67.6%) of 34 patients with stage II disease. In 175 patients with stage III-IV hypopharyngeal cancer, 90 patients were treated with chemotherapy, and 85 patients were treated by surgery after preoperative chemoradiotherapy. There were no significant differences in 5-year disease-specific survival rates between the two groups. However, 5-year local recurrence-free survival rates in radiotherapy group was 90.9% in T1, 59.7% in T2, 46.0% in T3, and 34.9% in T4. Patients with radiosensitive hypopharyngeal cancer seem to be curable with chemoradiotherapy, although local control rates should be improved.
All Science Journal Classification (ASJC) codes